PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS
Intro: Oral antiviral agents with differing modes of action are now available for the treatment of COVID-19. However, potentially life-threatening drug-drug interactions (DDIs) may occur if patients’ underlying co-morbidities are treated with medications that are contraindicated with ritonavir-conta...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | International Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223003508 |
| _version_ | 1827945154242150400 |
|---|---|
| author | C. Cameron W.-T. Chen W.-H. Tan Y. Chen C. Lam E. Igho-Osagie |
| author_facet | C. Cameron W.-T. Chen W.-H. Tan Y. Chen C. Lam E. Igho-Osagie |
| author_sort | C. Cameron |
| collection | DOAJ |
| description | Intro: Oral antiviral agents with differing modes of action are now available for the treatment of COVID-19. However, potentially life-threatening drug-drug interactions (DDIs) may occur if patients’ underlying co-morbidities are treated with medications that are contraindicated with ritonavir-containing antivirals. This study evaluated the prevalence and severity of potential DDIs (pDDIs) with ritonavir-containing COVID-19 oral antiviral therapy among the Australian population. Methods: Adult patients supplied with ≥1 medication between January 1, 2019, and December 31, 2019, were identified in the PBS10 dataset, a longitudinal, random 10% sample of the national Pharmaceutical Benefits Scheme (PBS) data for supplied prescriptions. Patients receiving medications that have pDDIs with a ritonavir-containing COVID-19 antiviral treatment were classified as the pDDI group, using data sources from University of Liverpool, Lexicomp®, or the US Food and Drugs Administration. Findings: Over 1,434,000 patients in the PBS10 were supplied with ≥1 medication during the study period. The majority (58.8%) had been prescribed at least one medication with pDDI with ritonavir-containing treatment. Among all patients with pDDIs, 43.3% of them were major or contraindicated, followed by moderate (15.1%), and minor pDDIs (1.9%). Patients with cancer had the highest prevalence of contraindicated or major pDDIs (79.5%), followed by dementia and/or Alzheimer's (77.2%), and diabetes (73.8%). Elderly patients (≥60 years old) also had a higher prevalence of contradicted or major pDDI (65.4%) than the general patient population. Conclusion: Our results demonstrated that one-third of the Australian adult population in the PBS10 dataset may be classified as contraindicated with ritonavir-containing COVID-19 therapies. The prevalence of pDDI is much higher in elderly patients and in patients with certain co-morbidities. Health care providers will need to evaluate patients carefully should they be eligible for COVID-19 oral antiviral treatments. Alternative therapies should be considered as patients may be precluded from being treated with ritonavir-containing therapies owing to pDDIs. |
| first_indexed | 2024-03-13T10:40:39Z |
| format | Article |
| id | doaj.art-0aa266f53e174230b5661af69efd7bda |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-03-13T10:40:39Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-0aa266f53e174230b5661af69efd7bda2023-05-18T04:38:41ZengElsevierInternational Journal of Infectious Diseases1201-97122023-05-01130S89PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMSC. Cameron0W.-T. Chen1W.-H. Tan2Y. Chen3C. Lam4E. Igho-Osagie5MSD Australia, CORE AP, Sydney, NSW, AustraliaMSD Taiwan, GMSA, Taipei, TaiwanCerner Enviza, Real-World Evidence, Singapore, SingaporeCerner Enviza, Real-World Evidence, Singapore, SingaporeProspection Pty Ltd, Real-World Evidence, Sydney, NSW, AustraliaMerck & Co., Inc., CORE, Rahway, NJ, United States of AmericaIntro: Oral antiviral agents with differing modes of action are now available for the treatment of COVID-19. However, potentially life-threatening drug-drug interactions (DDIs) may occur if patients’ underlying co-morbidities are treated with medications that are contraindicated with ritonavir-containing antivirals. This study evaluated the prevalence and severity of potential DDIs (pDDIs) with ritonavir-containing COVID-19 oral antiviral therapy among the Australian population. Methods: Adult patients supplied with ≥1 medication between January 1, 2019, and December 31, 2019, were identified in the PBS10 dataset, a longitudinal, random 10% sample of the national Pharmaceutical Benefits Scheme (PBS) data for supplied prescriptions. Patients receiving medications that have pDDIs with a ritonavir-containing COVID-19 antiviral treatment were classified as the pDDI group, using data sources from University of Liverpool, Lexicomp®, or the US Food and Drugs Administration. Findings: Over 1,434,000 patients in the PBS10 were supplied with ≥1 medication during the study period. The majority (58.8%) had been prescribed at least one medication with pDDI with ritonavir-containing treatment. Among all patients with pDDIs, 43.3% of them were major or contraindicated, followed by moderate (15.1%), and minor pDDIs (1.9%). Patients with cancer had the highest prevalence of contraindicated or major pDDIs (79.5%), followed by dementia and/or Alzheimer's (77.2%), and diabetes (73.8%). Elderly patients (≥60 years old) also had a higher prevalence of contradicted or major pDDI (65.4%) than the general patient population. Conclusion: Our results demonstrated that one-third of the Australian adult population in the PBS10 dataset may be classified as contraindicated with ritonavir-containing COVID-19 therapies. The prevalence of pDDI is much higher in elderly patients and in patients with certain co-morbidities. Health care providers will need to evaluate patients carefully should they be eligible for COVID-19 oral antiviral treatments. Alternative therapies should be considered as patients may be precluded from being treated with ritonavir-containing therapies owing to pDDIs.http://www.sciencedirect.com/science/article/pii/S1201971223003508 |
| spellingShingle | C. Cameron W.-T. Chen W.-H. Tan Y. Chen C. Lam E. Igho-Osagie PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS International Journal of Infectious Diseases |
| title | PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS |
| title_full | PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS |
| title_fullStr | PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS |
| title_full_unstemmed | PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS |
| title_short | PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS WITH RITONAVIR-CONTAINING COVID-19 MEDICATIONS AMONG THE ADULT PATIENT POPULATION IN AUSTRALIA: ANALYSIS OF PHARMACEUTICAL BENEFITS SCHEME 10% SAMPLE (PBS10) CLAIMS |
| title_sort | prevalence of potential drug drug interactions with ritonavir containing covid 19 medications among the adult patient population in australia analysis of pharmaceutical benefits scheme 10 sample pbs10 claims |
| url | http://www.sciencedirect.com/science/article/pii/S1201971223003508 |
| work_keys_str_mv | AT ccameron prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19medicationsamongtheadultpatientpopulationinaustraliaanalysisofpharmaceuticalbenefitsscheme10samplepbs10claims AT wtchen prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19medicationsamongtheadultpatientpopulationinaustraliaanalysisofpharmaceuticalbenefitsscheme10samplepbs10claims AT whtan prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19medicationsamongtheadultpatientpopulationinaustraliaanalysisofpharmaceuticalbenefitsscheme10samplepbs10claims AT ychen prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19medicationsamongtheadultpatientpopulationinaustraliaanalysisofpharmaceuticalbenefitsscheme10samplepbs10claims AT clam prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19medicationsamongtheadultpatientpopulationinaustraliaanalysisofpharmaceuticalbenefitsscheme10samplepbs10claims AT eighoosagie prevalenceofpotentialdrugdruginteractionswithritonavircontainingcovid19medicationsamongtheadultpatientpopulationinaustraliaanalysisofpharmaceuticalbenefitsscheme10samplepbs10claims |